@article { ISI:000280605900013,
	title = {Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis},
	journal = {Proceedings of the National Academy of Sciences of the United States of America},
	volume = {107},
	number = {31},
	year = {2010},
	month = {AUG},
	pages = {13608-13613},
	publisher = {NATL ACAD SCIENCES},
	address = {2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA},
	abstract = {<p>Therapeutic angiogenesis is an emerging paradigm for the management of ischemic pathologies. Proangiogenic Therapy is limited, however, by the current inability to deliver angiogenic factors in a sustained manner at the site of pathology. In this study, we investigated a unique nonglycosylated active fragment of hepatocyte growth factor/scatter factor, 1K1, which acts as a potent angiogenic agent in vitro and in a zebrafish embryo and a murine matrigel implant model. Furthermore, we demonstrate that nanoformulating 1K1 for sustained release temporally alters downstream signaling through the mitogen activated protein kinase pathway, and amplifies the angiogenic outcome. Merging protein engineering and nanotechnology offers exciting possibilities for the treatment of ischemic disease, and furthermore allows the selective targeting of downstream signaling pathways, which translates into discrete phenotypes.</p>},
	keywords = {cardiovascular disease, HGF/SF, ischemic disease, nanoparticle, protein engineering},
	issn = {0027-8424},
	doi = {10.1073/pnas.1006007107},
	author = {Roy, Rituparna Sinha and Soni, Shivani and Harfouche, Rania and Vasudevan, Pooja R. and Holmes, Oliver and de Jonge, Hugo and Rowe, Arthur and Paraskar, Abhimanyu and Hentschel, Dirk M. and Chirgadze, Dimitri and Blundell, Tom L. and Gherardi, Ermanno and Mashelkar, Raghunath Anant and Sengupta, Shiladitya}
}
@article {49859,
	title = {Proteome profile of stress test assessed cardiovascular disease risk-prone diabetic subjects},
	journal = {Journal of Cardiovascular Translational Research},
	volume = {18},
	year = {2025},
	month = {AUG},
	pages = {960-969},
	type = {Article},
	abstract = {<p>
	Cardiovascular disease (CVD) is the leading cause of death in the diabetic population. There is a need for specific predictive markers to assess CVD risk. The present study explored the plasma proteome profile of treadmill test (TMT) assessed diabetic stress test positive (DSTP) and diabetic stress test negative (DSTN) subjects by performing a SWATH-MS-based label-free quantitative mass spectrometry approach to identify differentially expressed proteins (DEPs). CVD-relevant DEPs were further validated using a targeted mass spectrometry approach (MRM-HR). It was observed that CO4B, PON1 and LUM exhibited considerable differential expression in both the MS approaches, and ROC analysis showed significant AUC (0.97, 0.79 and 0.77, respectively). Overall, the present study reports these proteins as potential alternative markers for TMT in assessing CVD risk. These markers can possibly overcome the limitations of TMT with further validation in the large cohort.Graphical AbstractAn overview of experimental approaches used in the current study. The study design depicts diabetic subjects assessed for cardiovascular risk by TMT or stress test. The experimental design shows the use of the SWATH-MS approach to identify differentially expressed proteins and validate CVD-related proteins with targeted MS approaches such as MRM-HR. Finally, CO4B, PON1 and LUM exhibited significant AUC in ROC analysis, indicating their potential marker capabilities to predict CVD in diabetic subjects.</p>
},
	keywords = {cardiovascular disease, Diabetes, Multiple reaction monitoring, Plasma markers, Proteome profile, Quantitative mass spectrometry},
	issn = {1937-5387},
	doi = {10.1007/s12265-025-10651-w},
	author = {Patil, Yugendra R. and Tiwari, Shalbha and Unnikrishnan, A. G. and Kulkarni, Mahesh J.}
}
